One-Year Medication Adherence and Persistence in Rheumatoid Arthritis in Clinical Practice: A Retrospective Analysis of Upadacitinib, Adalimumab, Baricitinib, and Tofacitinib.
Discontinuation
Janus kinase inhibitor
Medication adherence
Real-world
Rheumatoid arthritis
Treatment persistence
Tumor necrosis factor inhibitor
Upadacitinib
Journal
Advances in therapy
ISSN: 1865-8652
Titre abrégé: Adv Ther
Pays: United States
ID NLM: 8611864
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
received:
06
04
2023
accepted:
17
07
2023
medline:
14
9
2023
pubmed:
6
8
2023
entrez:
5
8
2023
Statut:
ppublish
Résumé
This study evaluated 12 months adherence and persistence among Janus kinase inhibitors (upadacitinib, baricitinib, tofacitinib) and adalimumab, a tumor necrosis factor inhibitor (TNFi), in patients with rheumatoid arthritis (RA). This retrospective analysis used administrative claims data from the Merative™ MarketScan In total, 6317 patients were included (683 upadacitinib, 3732 adalimumab, 132 baricitinib, 1770 tofacitinib). Compared with upadacitinib, patients initiating adalimumab [aOR (95% CI): 0.82 (0.69, 0.96)], baricitinib [0.46 (0.31, 0.68)], and tofacitinib [0.74 (0.62, 0.88)] were significantly less likely to achieve PDC ≥ 80%. Risk of treatment discontinuation was significantly higher in patients treated with adalimumab [aHR (95% CI): 1.14 (1.01, 1.29)], baricitinib [1.48 (1.16, 1.90)], and tofacitinib [1.22 (1.07, 1.38)] compared with upadacitinib. Mean time to discontinuation was 256 (upadacitinib), 249 (adalimumab), 221 (baricitinib), and 239 (tofacitinib) days. Similar results were observed in patients with prior TNFi use. Patients with RA, regardless of recent TNFi experience, initiating upadacitinib were significantly more likely to be adherent and less likely to discontinue therapy compared to adalimumab, baricitinib, and tofacitinib in the first 12 months of treatment.
Identifiants
pubmed: 37542646
doi: 10.1007/s12325-023-02619-6
pii: 10.1007/s12325-023-02619-6
pmc: PMC10499920
doi:
Substances chimiques
Adalimumab
FYS6T7F842
tofacitinib
87LA6FU830
Antirheumatic Agents
0
upadacitinib
4RA0KN46E0
baricitinib
ISP4442I3Y
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
4493-4503Informations de copyright
© 2023. The Author(s).
Références
Lin Y-J, Anzaghe M, Schülke S. Update on the pathomechanism, diagnosis, and treatment options for rheumatoid arthritis. Cells. 2020;9:880.
doi: 10.3390/cells9040880
pubmed: 32260219
pmcid: 7226834
Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2021;73:1108–23.
doi: 10.1002/art.41752
pubmed: 34101376
Smolen JS, Breedveld FC, Burmester GR, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016;75:3–15.
doi: 10.1136/annrheumdis-2015-207524
pubmed: 25969430
Smolen JS, Landewé RB, Bijlsma JW, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79:685–99.
doi: 10.1136/annrheumdis-2019-216655
pubmed: 31969328
Bergman MJ, Kivitz AJ, Pappas DA, et al. Clinical utility and cost savings in predicting inadequate response to anti-TNF therapies in rheumatoid arthritis. Rheumatol Ther. 2020;7:775–92.
doi: 10.1007/s40744-020-00226-3
pubmed: 32797404
pmcid: 7695768
Holdsworth EA, Donaghy B, Fox KM, Desai P, Collier DH, Furst DE. Biologic and targeted synthetic DMARD utilization in the united states: adelphi real world disease specific programme for rheumatoid arthritis. Rheumatol Ther. 2021;8:1637–49.
doi: 10.1007/s40744-021-00357-1
pubmed: 34487340
pmcid: 8572299
Hetland ML, Christensen IJ, Tarp U, et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum. 2010;62:22–32.
doi: 10.1002/art.27227
pubmed: 20039405
Bergman M, Zhou L, Patel P, Sawant R, Clewell J, Tundia N. Healthcare costs of not achieving remission in patients with rheumatoid arthritis in the United States: A retrospective cohort study. Adv Ther. 2021;38:2558–70.
doi: 10.1007/s12325-021-01730-w
pubmed: 33837497
pmcid: 8107161
Curtis JR, Fox KM, Xie F, et al. The economic benefit of remission for patients with rheumatoid arthritis. Rheumatol Ther. 2022;9:1329–45.
doi: 10.1007/s40744-022-00473-6
pubmed: 35834162
pmcid: 9510082
Karpes Matusevich AR, Duan Z, Zhao H, et al. Treatment sequences after discontinuing a tumor necrosis factor inhibitor in patients with rheumatoid arthritis: a comparison of cycling versus swapping strategies. Arthritis Care Res (Hoboken). 2021;73:1461–9.
doi: 10.1002/acr.24358
pubmed: 32558339
Wei W, Knapp K, Wang L, et al. Treatment persistence and clinical outcomes of tumor necrosis factor inhibitor cycling or switching to a new mechanism of action therapy: real-world observational study of rheumatoid arthritis patients in the United States with prior tumor necrosis factor inhibitor therapy. Adv Ther. 2017;34:1936–52.
doi: 10.1007/s12325-017-0578-8
pubmed: 28674959
pmcid: 5565674
Burmester GR, Kremer JM, Van den Bosch F, et al. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018;391:2503–12.
doi: 10.1016/S0140-6736(18)31115-2
pubmed: 29908669
Fleischmann R, Pangan AL, Song IH, et al. Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind, randomized controlled trial. Arthritis Rheumatol. 2019;71:1788–800.
doi: 10.1002/art.41032
pubmed: 31287230
Genovese MC, Fleischmann R, Combe B, et al. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. Lancet. 2018;391:2513–24.
doi: 10.1016/S0140-6736(18)31116-4
pubmed: 29908670
Rubbert-Roth A, Enejosa J, Pangan AL, et al. Trial of upadacitinib or abatacept in rheumatoid arthritis. N Engl J Med. 2020;383:1511–21.
doi: 10.1056/NEJMoa2008250
pubmed: 33053283
Smolen JS, Pangan AL, Emery P, et al. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. Lancet. 2019;393:2303–11.
doi: 10.1016/S0140-6736(19)30419-2
pubmed: 31130260
Stein JD, Lum F, Lee PP, Rich WL III, Coleman AL. Use of health care claims data to study patients with ophthalmologic conditions. Ophthalmology. 2014;121:1134–41.
doi: 10.1016/j.ophtha.2013.11.038
pubmed: 24433971
Souza AF, Da Silva MR, Dos Santos JB, Almeida AM, Acurcio FA, Alvares-Teodoro J. Medication adherence and persistence of psoriatic arthritis patients treated with biological therapy in a specialty pharmacy in Brazil: a prospective observational study. Pharm Practe (Grenada). 2021. https://doi.org/10.18549/PharmPract.2021.2.2312 .
doi: 10.18549/PharmPract.2021.2.2312
Murage MJ, Tongbram V, Feldman SR, et al. Medication adherence and persistence in patients with rheumatoid arthritis, psoriasis, and psoriatic arthritis: a systematic literature review. Patient Prefer Adherence. 2018;12:1483.
doi: 10.2147/PPA.S167508
pubmed: 30174415
pmcid: 6110273
Contreras-Yáñez I, Guaracha-Basáñez GA, Cuevas-Montoya M, de Jesús H-B, Pascual-Ramos V. Early persistence on therapy impacts drug-free remission: a case-control study in a cohort of Hispanic patients with recent-onset rheumatoid arthritis. Arthritis Res Ther. 2022;24:1–9.
doi: 10.1186/s13075-022-02884-w
Li L, Cui Y, Yin R, et al. Medication adherence has an impact on disease activity in rheumatoid arthritis: a systematic review and meta-analysis. Patient Prefer Adherence. 2017;11:1343.
doi: 10.2147/PPA.S140457
pubmed: 28831245
pmcid: 5553350
Peter ME, Zuckerman AD, DeClercq J, et al. Adherence and persistence in patients with rheumatoid arthritis at an integrated health system specialty pharmacy. J Manag Care Spec Pharm. 2021;27:882–90.
pubmed: 34185565
Pasma A, Schenk C, Timman R, et al. Does non-adherence to DMARDs influence hospital-related healthcare costs for early arthritis in the first year of treatment? PLoS One. 2017;12(2): e0171070.
doi: 10.1371/journal.pone.0171070
pubmed: 28152001
pmcid: 5289489
Merative™ MarketScan® Research Databases. 2023 [Available at: https://www.merative.com/documents/brief/marketscan-explainer-general ]. Accessed 10 July 2023.
Dalli LL, Kilkenny MF, Arnet I, et al. Towards better reporting of the proportion of days covered method in cardiovascular medication adherence: a scoping review and new tool TEN-SPIDERS. Br J Clin Pharmacol. 2022;88:4427–42.
doi: 10.1111/bcp.15391
pubmed: 35524398
Scheepers L, Jones G. AB0414 Drug persistence on janus kinase (JAK) inhibitors compared to biologic DMARDs in patients with rheumatoid arthritis: retrospective study in the Australian population. Ann Rheum Dis. 2022;81:1335.
doi: 10.1136/annrheumdis-2022-eular.4149
Harnett J, Gerber R, Gruben D, Koenig AS, Chen C. Evaluation of real-world experience with tofacitinib compared with adalimumab, etanercept, and abatacept in RA patients with 1 previous biologic DMARD: data from a US administrative claims database. J Manag Care Spec Pharm. 2016;22:1457–71.
pubmed: 27882833
Codullo V, Iannone F, Sinigaglia L, et al. Comparison of efficacy of first-versus second-line adalimumab in patients with rheumatoid arthritis: experience of the Italian biologics registries. Clin Exp Rheumatol. 2017;35:660–5.
pubmed: 28516879
Frazier-Mironer A, Dougados M, Mariette X, et al. Retention rates of adalimumab, etanercept and infliximab as first and second-line biotherapy in patients with rheumatoid arthritis in daily practice. Jt Bone Spine. 2014;81:352–9.
doi: 10.1016/j.jbspin.2014.02.014
Migliore A, Pompilio G, Integlia D, Zhuo J, Alemao E. Cycling of tumor necrosis factor inhibitors versus switching to different mechanism of action therapy in rheumatoid arthritis patients with inadequate response to tumor necrosis factor inhibitors: a Bayesian network meta-analysis. Ther Adv Musculoskelet Dis. 2021;13:1759720X211002682.
doi: 10.1177/1759720X211002682
pubmed: 33854570
pmcid: 8010806
Rubbert-Roth A, Szabó MZ, Kedves M, Nagy G, Atzeni F, Sarzi-Puttini P. Failure of anti-TNF treatment in patients with rheumatoid arthritis: the pros and cons of the early use of alternative biological agents. Autoimmun Rev. 2019;18: 102398.
doi: 10.1016/j.autrev.2019.102398
pubmed: 31639514
Fleischmann R, Bessette L, Sparks J, et al. POS0683 Efficacy and safety of upadacitinib in TNFi-IR patients with rheumatoid arthritis from three Phase 3 clinical trials. Ann Rheum Dis. 2022;81:618–9.
doi: 10.1136/annrheumdis-2022-eular.1800
Fleischmann RM, Genovese MC, Enejosa JV, et al. Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response. Ann Rheum Dis. 2019;78:1454–62.
doi: 10.1136/annrheumdis-2019-215764
pubmed: 31362993
Radawski C, Genovese MC, Hauber B, et al. Patient perceptions of unmet medical need in rheumatoid arthritis: a cross-sectional survey in the USA. Rheumatol Ther. 2019;6:461–71.
doi: 10.1007/s40744-019-00168-5
pubmed: 31385264
pmcid: 6702617
Rendas-Baum R, Wallenstein GV, Koncz T, et al. Evaluating the efficacy of sequential biologic therapies for rheumatoid arthritis patients with an inadequate response to tumor necrosis factor-α inhibitors. Arthritis Res Ther. 2011;13:1–15.
doi: 10.1186/ar3249